A phase II study to investigate the effect of Glivec (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma.
Phase of Trial: Phase II
Latest Information Update: 08 May 2012
At a glance
- Drugs Imatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR367).
- 16 Apr 2007 New trial record.